Longevity — sector dashboard · fobi

Sign in Sign up free

Graveyard

Turn Biotechnologies
Turn Biotechnologies, the Stanford-spun cellular-reprogramming startup behind the ERA (Epigenetic Reprogramming of Aging) mRNA platform, wound down in 2026 after failing to secure a going-concern sale. A September 2025 letter of intent for Nasdaq-listed Klotho Neurosciences to buy select assets lapsed unconsummated in October 2025, and the company's remaining assets — the ERA platform and its eTurna mRNA-delivery IP — were then put to a competitive auction. South Korea's Daewoong Pharmaceutical, parent of Turn's former licensee HanAll Biopharma, was selected as the winning bidder in a live auction on May 6, 2026, with the deal signed later that month; the auction price was not disclosed. No Turn Bio founder or executive was quoted in the acquisition coverage and its website went dark, consistent with a distressed wind-down and asset sale rather than a going-concern acquisition. The ERA technology now sits inside Daewoong/HanAll.
Obituary
Unity Biotechnology
Unity Biotechnology IPO'd on Nasdaq in 2018 as the leading public senolytics company but never delivered a successful pivotal program. After an early osteoarthritis effort failed, its lead eye drug UBX1325 missed the primary endpoint in the Phase 2b ASPIRE study in diabetic macular edema; in May 2025 Unity released the complete 36-week results, closed ASPIRE, and laid off essentially its entire remaining workforce while exploring strategic alternatives. Nasdaq deemed the company a public shell and suspended its stock in July 2025, moving it to OTC Pink under the symbol UNBX. On September 26, 2025 Unity filed a certificate of dissolution in Delaware after stockholders approved a plan of liquidation, terminating its leases and ending the company.
Obituary
AgeX Therapeutics
AgeX Therapeutics was spun out of BioTime in 2017 to develop pluripotent stem-cell and induced Tissue Regeneration therapies for aging, but it ran chronically short of capital and leaned on loans from major shareholder Juvenescence. On March 26, 2024 AgeX completed a reverse merger into Serina Therapeutics; immediately before closing, substantially all of AgeX's legacy aging assets — including its interests in ReCyte Therapeutics and Reverse Bioengineering and the iTR intellectual property — were transferred into a vehicle called UniverXome that absorbed AgeX's indebtedness. The combined public company operated as Serina Therapeutics and pivoted to Serina's POZ polymer drug-delivery platform, abandoning AgeX's aging focus. In December 2024 Juvenescence purchased UniverXome to clear about $11.2 million of debt, completing AgeX's disappearance as an independent aging company.
Obituary
resTORbio
resTORbio was a Novartis spinout founded in 2016 to drug the mTOR aging pathway, licensing the TORC1 inhibitor RTB101 and IPO'ing on Nasdaq in 2018 as a leading geroscience company. In November 2019 its pivotal Phase 3 PROTECTOR 1 trial of RTB101 to prevent clinically symptomatic respiratory illness in older adults missed its primary endpoint, the stock fell sharply, and the company halted the respiratory program. In 2020 resTORbio entered a reverse merger with Adicet Bio, executing a 7:1 reverse stock split at closing; the combined company adopted the name Adicet Bio, Inc. and refocused entirely on off-the-shelf allogeneic gamma-delta CAR-T cell therapies for oncology, abandoning resTORbio's aging pipeline and ending it as an independent geroscience company.
Obituary